[5]Birocchi S, Podda GM, Manzoni M,et al. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets. 2021;32(2):216–226. [6]中华医学会血液学分会血栓...
7.Yu Y, Wang M, Hou Y, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter,...
[13]Desouza S, Angelini D. Updated guidelines for immune thrombocytopenic purpura: Expanded management options [J]. Cleve Clin J Med, 2021, 88(12): 664-668. [14]Wei Y, Ji X B, Wang Y W, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a p...
中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2012年版)[J].中华血液学杂志, 2012, 33(11): 975-977. DOI: 10.3760/cma.j.issn.0253-2727.2012.11.021 Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission ...
Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopeniadoi:10.1016/j.medcle.2021.07.003María L. LozanoMiguel A. SanzVicente VicenteMedicina Clínica (English Edition)
1.Miano M, Ramenghi U, Russo G, Rubert L, Barone A, Tucci F, Farruggia P, Petrone A, Mondino A, Lo Valvo L, Crescenzio N, Bellia F, Olivieri I, Palmisani E, Caviglia I, Dufour C, Fioredda F. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Eva...
Existing guidelines describe the management and treatment of most patients who, overall, do well, even if they present with chronic disease, and they are usually not at a high risk for bleeding; however, a small percentage of patients is refractory and difficult to manage. Patients classified ...
新版ITP新药新消息汇编ITP新药新消息奥赛康申报一罕见病药物该品国内市场尚属空白国家食药监总局CFDA网站显示,奥赛康申报临床的3,1类造血新药艾曲泊帕原料药和片剂获受理,目前,艾曲泊帕原研药尚未进入中国市场,也无国内企业生产该
IL-18, IL-1 p and HMGB1 significantly decreased after treatment (P<0.05). After treatment, JSLRP3, ASC, and Caspase-1mRNA levels in peripheral blood mononuclear cells were significantly lower than those before treatment (P<0.05). NLRP3 protein expression decreased significantly after treatment...
[12] Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multi...